{
    "root": "36228fcb-d91b-a123-e063-6394a90a6d77",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Duloxetine",
        "suffix": {
            "text": "Delayed-Release"
        }
    },
    "value": "20250527",
    "ingredients": [
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "DULOXETINE HYDROCHLORIDE",
            "code": "9044SC542W"
        }
    ],
    "indications": "duloxetine delayed-release capsules indicated treatment : major depressive disorder adults generalized anxiety disorder adults pediatric patients 7 years age older diabetic peripheral neuropathic pain adults fibromyalgia adults pediatric patients 13 years age older chronic musculoskeletal pain adults",
    "contraindications": "take duloxetine delayed-release capsules daily , without food . swallow whole ; crush , chew , open capsule ( 2.1 ) indication starting dose target dose maximum dose mdd ( 2.2 ) 40 mg/day 60 mg/day acute treatment : 40 mg/day ( 20 mg twice daily ) 60 mg/day ( daily 30 mg twice daily ) ; maintenance treatment : 60 mg/day 120 mg/day gad ( 2.3 ) adults 60 mg/day 60 mg/day ( daily ) 120 mg/day geriatric 30 mg/day 60 mg/day ( daily ) 120 mg/day pediatrics ( 7 17 years age ) 30 mg/day 30 60 mg/day ( daily ) 120 mg/day dpnp ( 2.4 ) 60 mg/day 60 mg/day ( daily ) 60 mg/day fm ( 2.5 ) adults pediatrics ( 13 17 years age ) 30 mg/day 60 mg/day ( daily ) 60 mg/day chronic musculoskeletal pain ( 2.6 ) 30 mg/day 60 mg/day ( daily ) 60 mg/day discontinuing duloxetine delayed-release capsules : gradually reduce avoid discontinuation symptoms ( 2.8 , 5.7 )",
    "warningsAndPrecautions": "duloxetine delayed-release capsules , usp available following strengths , colors , imprints , presentation : 60 mg , body color : opaque ochre cap color : opaque green , cap imprint : b , body imprint : 748 ndc : 70518-0122-00 ndc : 70518-0122-01 ndc : 70518-0122-02 ndc : 70518-0122-03 ndc : 70518-0122-04 ndc : 70518-0122-05 packaging : 30 1 blister pack packaging : 30 1 bottle plastic packaging : 60 1 bottle plastic packaging : 100 1 box packaging : 1 1 pouch packaging : 90 1 bottle plastic equivalent duloxetine base store 25°c ( 77°f ) ; excursions permitted 15-30°c ( 59-86°f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "maois intended treat psychiatric disorders duloxetine delayed-release capsules within 5 days stopping treatment duloxetine delayed-release capsules contraindicated increased risk serotonin syndrome . duloxetine delayed-release capsules within 14 days stopping maoi intended treat psychiatric disorders contraindicated [ ( 2.8 ) ( 5.4 ) ] . starting duloxetine delayed-release capsules patient treated maois linezolid intravenous methylene blue also contraindicated increased risk serotonin syndrome [ ( 2.9 ) ( 5.4 ) ] .",
    "indications_original": "Duloxetine delayed-release capsules is indicated for the treatment of:\n                  \n                     Major depressive disorder in adults\n                     Generalized anxiety disorder in adults and pediatric patients 7 years of age and older\n                     Diabetic peripheral neuropathic pain in adults\n                     Fibromyalgia in adults and pediatric patients 13 years of age and older\n                     Chronic musculoskeletal pain in adults",
    "contraindications_original": "Take Duloxetine delayed-release capsules once daily, with or without food. Swallow whole; do not crush, chew, or open capsule ( 2.1 ) Indication Starting Dose Target Dose Maximum Dose MDD ( 2.2 ) 40 mg/day to 60 mg/day Acute Treatment: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or as 30 mg twice daily); Maintenance Treatment: 60 mg/day 120 mg/day GAD ( 2.3 ) Adults 60 mg/day 60 mg/day (once daily) 120 mg/day Geriatric 30 mg/day 60 mg/day (once daily) 120 mg/day Pediatrics (7 to 17 years of age) 30 mg/day 30 to 60 mg/day (once daily) 120 mg/day DPNP ( 2.4 ) 60 mg/day 60 mg/day (once daily) 60 mg/day FM ( 2.5 ) Adults and Pediatrics (13 to 17 years of age) 30 mg/day 60 mg/day (once daily) 60 mg/day Chronic Musculoskeletal Pain ( 2.6 ) 30 mg/day 60 mg/day (once daily) 60 mg/day Discontinuing Duloxetine delayed-release capsules: Gradually reduce dosage to avoid discontinuation symptoms ( 2.8 , 5.7 )",
    "warningsAndPrecautions_original": "Duloxetine delayed-release capsules, USP are available in the following strengths, colors, imprints, and presentation:\n                  60 mg, Body Color:Opaque ochre Cap Color: Opaque green, Cap imprint: B, Body imprint: 748\n                  \n                  NDC: 70518-0122-00\n                  NDC: 70518-0122-01\n                  NDC: 70518-0122-02\n                  NDC: 70518-0122-03\n                  NDC: 70518-0122-04\n                  NDC: 70518-0122-05\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC\n                  PACKAGING: 60 in 1 BOTTLE PLASTIC\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  \n                  equivalent to duloxetine base\n                  Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "The use of MAOIs intended to treat psychiatric disorders with Duloxetine delayed-release capsules or within 5 days of stopping treatment with Duloxetine delayed-release capsules is contraindicated because of an increased risk of serotonin syndrome. The use of Duloxetine delayed-release capsules within 14 days of stopping an MAOI intended to treat psychiatric disorders is contraindicated\n \n  [see\n  \n   Dosage and Administration (2.8)and\n  \n   Warnings and Precautions (5.4)].\n \n  \n                  \n                  Starting Duloxetine delayed-release capsules in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome\n \n  [see\n  \n   Dosage and Administration (2.9)and\n  \n   Warnings and Precautions (5.4)]."
}